254 related articles for article (PubMed ID: 33596851)
1. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
2. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract][Full Text] [Related]
3. The negative feedback between miR-143 and DNMT3A regulates cisplatin resistance in ovarian cancer.
Han X; Liu D; Zhou Y; Wang L; Hou H; Chen H; Zhang L; Chen W; Li X; Zhao L
Cell Biol Int; 2021 Jan; 45(1):227-237. PubMed ID: 33090550
[TBL] [Abstract][Full Text] [Related]
4. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
[TBL] [Abstract][Full Text] [Related]
5. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
7. Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer.
Cai X; Shi S; Chen G; Zhong M; Yang Y; Mai Z; Tian Y; Tan J; He L; Cui C; Yu Z; Wang X
Acta Biomater; 2023 Mar; 158():560-570. PubMed ID: 36596434
[TBL] [Abstract][Full Text] [Related]
8. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
9. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
10. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
12. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
13. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
14. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
15. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
[TBL] [Abstract][Full Text] [Related]
16. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
17. Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells.
Abe T; Gotoh S; Higashi K
Biochem Pharmacol; 1999 Jul; 58(1):69-76. PubMed ID: 10403520
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
20. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
